Clinical Trial Update: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial [Phase 3]

View source ↗

Summary

Phase 3 SUMMIT trial evaluating tirzepatide in obesity and heart failure with preserved ejection fraction has completed; results were posted on 2025-08-20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Obesity

Drugs mentioned

• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | Status: COMPLETED | Results posted: 2025-08-20